Viral Infectious Diseases Articles & Analysis
39 news found
The Centers for Disease Control and Prevention describe Methicillin-resistant Staphylococcus aureus (MRSA) as a type of staph that can be resistant to several antibiotics. The agency cautions that anyone can get a MRSA infection or carry MRSA. The risks increase for those with hospitalizations or nursing home stays, skin-to-skin contact with others, and exposure to crowded or unhygienic places. ...
Infectious diseases are disorders caused by organisms — such as bacteria, viruses, or parasites. ...
As an expert in providing solutions to assist virology and microbiology research, Creative Diagnostics is proud to announce the launch of its innovative Influenza A Virus Mouse Models to assess the impact of virus-host interactions. These mouse models can facilitate comprehensive research into the pathogenesis, immune response, and efficacy of antiviral treatments against influenza A infections. ...
Tuberculosis (TB) and Human Immunodeficiency Virus (HIV) are major global health threats. Their interaction worsens disease severity, as HIV reduces CD4+ T cells, making individuals more vulnerable to TB. Despite progress, an effective animal model that mimics human immune response during HIV/TB co-infection has been lacking, hindering treatment and vaccine development. Bohorguez et al. ...
Fungal Disease Awareness Week (FDAW) kicks off today and runs through the 22nd. The Centers for Disease Control and Prevention (CDC) created FDAW to highlight the importance of recognizing, treating, and preventing serious fungal diseases. According to the CDC: Many people are affected by fungal diseases at different points in their lives, whether dealing with a somewhat common ringworm ...
Chimeric also receives exclusive global rights to the CORE-NK platform for immune disorders and viral infectious diseases. Chimeric’s exclusive global license from CWRU covers patent rights, knowhow, and biological materials in relation to therapeutic products for the NKF feeder cell line and CORE-NK manufacturing process in the fields of ...
Chimeric also receives exclusive global rights to the CORE-NK platform for immune disorders and viral infectious diseases. “We are excited to continue building on our collaboration with CWRU with the definitive license agreement for the CORE-NK platform,” said Jennifer Chow, CEO and Managing Director of Chimeric. ...
XPhyto’s pipeline of biosensor screening products for inflammatory, bacterial and viral infectious diseases includes stomatitis, periimplantitis, periodontitis, group A strep, influenza A, and covid-19. ...
The company expects to provide further updates on its oral health and infectious disease screening test programs in the coming weeks. XPhyto’s pipeline of biosensor screening products for inflammatory, bacterial and viral infectious diseases includes stomatitis, periimplantitis, periodontitis, group A ...
According to the report of World Health Organization (WHO) on May 21, more than 120 confirmed or suspected cases of monkeypox, a rare viral disease seldom detected outside Africa, have been reported in at least 12 non-epidemic countries around the world, including more than 20 confirmed cases in Portugal, Spain and the UK. At present, there are no relevant death cases. There is evidence that ...
The Toronto-based research reports a decrease of viral infectivity of 90% of SARS-CoV-2 patient samples using Ondine’s nasal antimicrobial photodynamic disinfection (aPDT), with 70% of patient samples completely inactivated from a single 5-minute treatment. The nose is the primary location for SARS-CoV-2 entry and it has a central role in transmission and disease severity. The Journal ...
Phase 2 study completed enrollment ahead of schedule Posoleucel well-tolerated with no cases of graft rejection observed to date Overall decline in median BK viral load among patients completing 12 weeks of dosing with posoleucel or placebo (2:1 randomization) Posoleucel detected up to 12 weeks after last infusion Topline, unblinded study results from all 61 patients expected to be released ...
ByKalaris
(NASDAQ: OPK), a multinational biopharmaceutical and diagnostics company, today announced the acquisition of ModeX Therapeutics, Inc. a privately held biotechnology company focused on developing innovative multi-specific immune therapies for cancer and infectious diseases. OPKO acquired ModeX for $300 million in OPKO common stock. ...
“The multi-virus prevention approach is the most transformative use of posoleucel and, accordingly, we are seeing strong enthusiasm from hematologists and infectious disease specialists as we expand our Phase 3 study sites and ...
ByKalaris
AlloVir (Nasdaq: ALVR), a late clinical-stage allogeneic T cell immunotherapy company, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to its lead investigational multi-virus-specific T cell therapy, posoleucel, for the prevention of clinically significant infections and disease from six devastating viruses ...
ByKalaris
AlloVir (Nasdaq: ALVR), a late-clinical stage allogeneic T-cell immunotherapy company, today announced the appointment of Shawn Tomasello to its Board of Directors. Ms. Tomasello brings more than 35 years of broad experience building and leading commercial organizations in the life sciences industry, with specific expertise in cell and gene therapy. “We’re thrilled to welcome Shawn ...
ByKalaris
As 90% of allo-HCT patients reactivate at least one of these viruses, there is a large global market opportunity for the prevention of devastating viral diseases, with an estimated addressable patient population of 40,000 allo-HCT patients annually. ...
ByKalaris
Health Technology Innovations, Inc. (HTI) is excited to announce that Dr. Doug Kawahara is joining HTI as Senior Advisor for AI/ML in Drug Discovery. Dr. Kawahara brings extensive experience in drug discovery and development to HTI. He is currently President & CEO of Elex Biotech (Portland, OR), a company developing novel drugs for the treatment of arrhythmia and heart failure. Previously, ...
Dr Arun Chandavarkar, Managing Director, Biocon Biologics Ltd., says the structure of the strategic alliance with Serum Institute Life Sciences provides Biocon Biologics with an asset light and accelerated entry into the often overlooked infectious diseases segment. Having established capabilities and a track record of success in biologics, Biocon ...
ByBiocon
AlloVir (Nasdaq: ALVR), a late clinical-stage allogeneic T cell immunotherapy company, today announced that Diana Brainard, M.D., Chief Executive Officer, will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on February 18, 2022, at 10:00 a.m. EST. A live webcast of the fireside chat will be available on the Investors & Press section of the AlloVir ...
ByKalaris